Study Information
Status: Active, Not Recruiting
Study Details
View study details on clinicaltrials.gov.
Locations
East Bay
Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
Description
This study will evaluate the safety and efficacy of the injectable drug cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected cisgender men and transgender women who have sex with men (MSM and TGW).
Principal Investigator
Recruitment Information
Please note that trial statuses change frequently. For the most up-to-date information, please contact the Research Department at (510) 204-5571.